DocSym
β
Searchsearch
Search
(H51.2) Internuclear ophthalmoplegia
More details coming soon
17 991 in individuals diagnosis internuclear ophthalmoplegia confirmed
Diagnosis internuclear ophthalmoplegia is diagnosed Women are 26.50% more likely than Men
6 612
Men receive the diagnosis internuclear ophthalmoplegia
0 (less than 0.1%)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
11 379
Women receive the diagnosis internuclear ophthalmoplegia
0 (less than 0.1%)Died from this diagnosis.
Risk Group for the Disease internuclear ophthalmoplegia - Men and Women aged 5-9
In Men diagnosis is most often set at age 0-29, 40-54, 65-79
Less common in men the disease occurs at Age 30-39, 55-64, 80-95+Less common in women the disease occurs at Age 50-54, 90-95+
In Women diagnosis is most often set at age 0-49, 55-89
Disease Features internuclear ophthalmoplegia
Absence or low individual and public risk
Internuclear ophthalmoplegia - what does this mean
Internuclear ophthalmoplegia is caused by damage to the medial longitudinal fasciculus, a nerve tract located in the brainstem that connects the medial rectus muscles on both sides of the eye. this damage disrupts the normal coordination of the eyes, resulting in an inability to turn the eyes outward together (adduction) on the affected side.
What happens during the disease - internuclear ophthalmoplegia
Internuclear ophthalmoplegia is a condition caused by damage to the medial longitudinal fasciculus (mlf), a nerve bundle connecting the abducens nerve nucleus in the brainstem to the oculomotor nerve nucleus. this damage can be caused by multiple sclerosis, stroke, trauma, or certain medications. the primary symptom is an inability to move the eyes in a horizontal direction, due to the abducens nerve being unable to send signals to the oculomotor nerve. this results in a decreased range of motion in the affected eye, and can cause double vision.
Clinical Pattern
More details coming soon
How does a doctor diagnose
- Physical examination of the eye and facial muscles
- Neurological examination
- Brain MRI to assess the brain stem and adjacent structures
- Brainstem Auditory Evoked Potential (BAEP) test
- Visual Evoked Potential (VEP) test
- Electroencephalogram (EEG) to look for abnormal brain activity
- Blood tests to rule out other causes of ophthalmoplegia
Treatment and Medical Assistance
Main goal of the treatment: Improve oculomotor nerve function and reduce symptoms of internuclear ophthalmoplegia.
- Prescribing corticosteroids to reduce inflammation
- Prescribing medications to reduce nerve damage
- Prescribing medications to reduce muscle spasticity
- Prescribing medications to reduce pain
- Physical therapy to improve eye movement
- Occupational therapy to improve daily activities
- Surgery to correct any structural abnormalities
- Vestibular rehabilitation to reduce dizziness
- Counseling to help manage stress and anxiety
8 Days of Hospitalization Required
Average Time for Outpatient Care Not Established
Internuclear ophthalmoplegia - Prevention
Internuclear ophthalmoplegia is a rare neurological disorder that can be prevented by maintaining a healthy lifestyle, avoiding smoking, and controlling underlying conditions such as diabetes and hypertension. regular physical activity and a balanced diet can also help reduce the risk of developing this condition.